Tyrosinemia Type III

1. Disease Information

Overview. Tyrosinemia type III is the rarest of the three genetic tyrosinemias — an autosomal recessive inborn error caused by biallelic loss-of-function variants in HPD, encoding 4-hydroxyphenylpyruvate dioxygenase (HPD/HPPD), the second enzyme of the tyrosine catabolic pathway. Loss of HPD activity blocks conversion of 4-hydroxyphenylpyruvate to homogentisate, producing hypertyrosinemia and massive urinary excretion of 4-hydroxyphenyl organic acids. Critically, because the block sits upstream of the maleylacetoacetate/fumarylacetoacetate steps, no succinylacetone or other hepatotoxic intermediate is generated — reported patients have normal liver and renal function and no eye or skin disease. This is the mechanistic feature that separates HT III from tyrosinemia type I (FAH; liver failure, hepatocellular carcinoma) and type II (TAT; oculocutaneous disease). The clinical picture is dominated by variable neurodevelopmental manifestations, but the causal route from tyrosine elevation to neurological injury is unresolved (PMID:16602095; PMID:11916315; PMID:10942115).

Key identifiers: - MONDO:0010162 (tyrosinemia type III) - OMIM #276710 (TYRSN3, disease); OMIM 609695 (HPD, gene) - Orphanet ORPHA:69723 - ICD-10: E70.2 (Disorders of tyrosine metabolism); ICD-11: 5C50.0 (Disorders of tyrosine metabolism) - MeSH: Tyrosinemias (D020176) - Enzyme: EC 1.13.11.27; UniProt P32754* (human HPD)

Synonyms / alternative names: Hereditary tyrosinemia type III; HT III; 4-hydroxyphenylpyruvate dioxygenase deficiency; HPD deficiency; tyrosinemia due to 4-hydroxyphenylpyruvate dioxygenase deficiency; TYRSN3.

Data provenance: Aggregated disease-level resources (OMIM, Orphanet, HPO, MONDO) plus individual patient case reports. No EHR-cohort data exist owing to rarity.

Sources: OMIM #276710, Wikipedia: Tyrosinemia type III, StatPearls: Hypertyrosinemia.

2. Etiology

Primary cause (genetic). Biallelic (homozygous or compound heterozygous) pathogenic variants in HPD (12q24.31) causing deficient 4-hydroxyphenylpyruvate dioxygenase activity. This is a monogenic Mendelian defect; there are no established environmental, infectious, or mechanistic non-genetic causes.

"Tyrosinemia type III (OMIM 276710) is an autosomal recessive disorder caused by the deficiency of 4-hydroxyphenylpyruvate dioxygenase (HPD), the second enzyme in the tyrosine catabolic pathway." — PMID:10942115

Genetic risk factors. The only established risk factor is inheritance of two pathogenic HPD alleles. Consanguinity raises the risk of homozygosity (several reported families are consanguineous). No susceptibility loci or modifier genes have been mapped (the case count is far too small for association studies).

Environmental risk factors. None causal. Dietary protein/tyrosine intake modulates the biochemical burden (higher intake → higher plasma tyrosine) but does not cause the disease. Note the important differential: transient tyrosinemia of the newborn (the most common cause of neonatal hypertyrosinemia, ~1 in 10 newborns) is non-genetic, attributed to hepatic immaturity/prematurity and relative ascorbate (vitamin C) deficiency, and must be distinguished from HT III.

Protective factors. No genetic protective variants documented. Early dietary tyrosine/phenylalanine restriction is the candidate protective/modifying intervention, though its disease-modifying effect on neurological outcome is unproven (see §12).

Gene–environment interaction. The principal G×E axis is genotype (HPD residual activity) × dietary tyrosine load determining circulating tyrosine — but strikingly, neither genotype severity nor tyrosine level predicts neurological phenotype (PMID:10942115), so any G×E model for the clinical outcome remains speculative.

Sources: PMID:10942115, PMID:11916315; Wadsworth NBS: Tyrosinemia type III; MedlinePlus Genetics: Tyrosinemia.

3. Phenotypes

The phenotype is bimodal by ascertainment: screening-detected individuals may be asymptomatic with normal development, while clinically-ascertained individuals present with neurological disease after the neonatal period. Because published denominators are unreliable, frequency bands are deliberately omitted (per curation SOP — omit rather than fabricate).

Key characteristics. Onset of neurological features is typically post-neonatal (infancy–childhood). Severity is highly variable and does not correlate with plasma tyrosine level or genotype — a defining and unusual feature of this disorder:

"No correlation of the severity of the mutation and enzyme deficiency and mental function has been found; neither do the recorded tyrosine levels correlate with the clinical phenotype." — PMID:10942115

"Presented case may suggest that high tyrosine concentration itself does not participate directly in neuronal damage described in patients with tyrosinemia type 3." — PMID:28649543 (asymptomatic girl, serum tyrosine 425–535 µmol/L; ref interval 29–86)

Notable absences (discriminating negatives). No hepatic disease, no renal tubular dysfunction, no corneal keratopathy/photophobia, no palmoplantar keratoderma — the features that define types I and II respectively:

"All have had normal liver and renal function and none has skin or eye abnormalities." — PMID:11916315

Quality-of-life impact. Not formally measured (no EQ-5D/SF-36/PROMIS data). Burden, where present, is confined to the neurodevelopmental/educational domain; screened-and-treated individuals may have normal function.

4. Genetic / Molecular Information

Causal gene: HPD (HGNC:5147; NCBI Gene 3242; Ensembl ENSG00000158104), chromosome 12q24.31, 14 exons, encoding 4-hydroxyphenylpyruvate dioxygenase (UniProt P32754; 393 aa; functions as a homodimer in humans).

Pathogenic variants (from the small reported allele set): - First mutation survey (PMID:10942115): 4 presumed pathogenic variants — 2 missense + 2 nonsense — across 3 unrelated families (4 homozygotes, 1 compound heterozygote). - Homozygous missense p.Ala268Val (A268V) in an HT III patient (PMID:11073718). - Compound heterozygous c.731C>T (p.Ala244Val / A244V) + c.656C>T (p.Thr219Met / T219M) in a Chinese girl (PMID:37817461). - Homozygous splice-donor IVS11+1G>A (intron 11) in a newborn-screened boy (PMID:23036342). - Novel splice-site variant in a patient with developmental delay + ventriculomegaly (PMID:35707594). - ClinVar records include NM_002150.3(HPD):c.774T>G (p.Tyr258Ter) associated with HT III.

Variant classes represented: missense, nonsense, and splice-site. All are loss-of-function in effect. Population allele frequencies (gnomAD) are consistent with individually ultra-rare alleles; no common founder allele is established. All variants are germline; somatic origin is not relevant.

"We have identified four presumed pathogenic mutations (two missense and two nonsense mutations) in the HPD gene in three unrelated families encompassing four homozygous individuals and one compound heterozygous individual with tyrosinemia type III." — PMID:10942115

One gene, two diseases (allelic disorders). HPD variants cause two distinct entities: biallelic LOF → autosomal recessive tyrosinemia type III; the heterozygous p.Ala33Thr (A33T) change → autosomal dominant hawkinsinuria (MONDO:0007700, OMIM 140350):

"These findings support the hypothesis that alterations in the structure and activity of HPD are causally related to two different metabolic disorders, tyrosinemia type III and hawkinsinuria." — PMID:11073718

Modifier genes / epigenetics / chromosomal abnormalities. None established (cohort too small). No epigenetic mechanism or structural/cytogenetic abnormality is implicated.

Sources: PMID:10942115, PMID:11073718, PMID:37817461, PMID:23036342, PMID:35707594; OMIM *609695; ClinVar RCV000001640; GTR HPD.

5. Environmental Information

• Environmental / occupational toxins: None causal. Of mechanistic interest, HPPD-inhibitor herbicides (triketones, e.g. sulcotrione/mesotrione; the drug nitisinone/NTBC is the pharmaceutical analog) chemically phenocopy the enzyme block — relevant to the pharmacology discussion in §12, not to disease etiology.
• Lifestyle / dietary factors: Dietary protein (tyrosine + phenylalanine) intake governs the magnitude of hypertyrosinemia and is the target of therapy; it is a modulator, not a cause.
• Infectious agents: Not applicable.

6. Mechanism / Pathophysiology

Pathway context. Tyrosine catabolism proceeds: TAT → HPD → HGD → GSTZ1 → FAH. The reactions are: tyrosine →(TAT)→ 4-hydroxyphenylpyruvate →(HPD)→ homogentisate →(HGD)→ maleylacetoacetate → fumarylacetoacetate →(FAH)→ fumarate + acetoacetate. HT III is the block at the HPD (second) step (KEGG map00350, tyrosine metabolism; Reactome R-HSA-8963684 tyrosine catabolism).

Causal chain (upstream → downstream):

1. [Trigger, MOLECULAR] 4-Hydroxyphenylpyruvate dioxygenase deficiency. Biallelic LOF HPD variants abolish/reduce HPD activity, blocking 4-hydroxyphenylpyruvate → homogentisate. Expression is principally hepatic, with lesser renal expression.

2. Gene: HPD (hgnc:5147). Molecular function: GO:0003868 4-hydroxyphenylpyruvate dioxygenase activity (DECREASED). Process: GO:0006572 L-tyrosine catabolic process (DECREASED). Product homogentisate (CHEBI:16169) DECREASED. Locations: UBERON:0002107 liver, UBERON:0002113 kidney.

   "The enzyme 4-hydroxyphenylpyruvic acid dioxygenase (HPD) catalyzes the reaction of 4-hydroxyphenylpyruvic acid to homogentisic acid in the tyrosine catabolism pathway." — PMID:11073718

3. [Central effector, ORGANISM] Hypertyrosinemia + phenolic-metabolite accumulation. Substrate proximal to the block accumulates: L-tyrosine (CHEBI:17895) INCREASED, 4-hydroxyphenylpyruvate (CHEBI:15999) INCREASED. Because the block is upstream of maleyl-/fumaryl-acetoacetate, succinylacetone is NOT produced → no hepatorenal toxicity (the discriminant vs type I).

   "...an autosomal recessive disorder characterized by elevated levels of blood tyrosine and massive excretion of tyrosine derivatives into urine." — PMID:11073718

4. [Biomarker, ORGANISM] Urinary 4-hydroxyphenyl organic acids — 4-hydroxyphenylpyruvate, 4-hydroxyphenyllactate, 4-hydroxyphenylacetate (CHEBI:18101) INCREASED; diagnostic organic-acid signature.

5. [Consequence, ORGANISM] Neurodevelopmental dysfunction (intellectual disability, developmental delay, ataxia, seizures, ADHD). This edge is curated INDIRECT / UNKNOWN INTERMEDIATES: the mediator is unresolved because tyrosine level, residual enzyme activity, and genotype all fail to predict the phenotype (PMID:10942115, PMID:28649543).

Enzyme biochemistry / protein dysfunction. HPD is a non-heme Fe(II)-dependent α-keto acid dioxygenase (EC 1.13.11.27). It performs an unusual single-cycle reaction — oxidative decarboxylation + side-chain 1,2-migration + aromatic hydroxylation — converting 3-(4-hydroxyphenyl)pyruvate + O₂ → homogentisate + CO₂. The catalytic non-heme iron is coordinated by a 2-His-1-carboxylate facial triad (His/His/Glu). Pathogenic missense variants are predicted to impair catalysis/stability; nonsense and splice variants cause loss of enzyme protein (in the mouse model, exon skipping and undetectable subunit; see §15).

Cellular processes / tissue-damage mechanism. The proximate defect is a hepatic/renal metabolic block; there is no fibrosis, apoptosis cascade, or inflammatory tissue destruction (unlike type I). The neurological injury mechanism is unknown — candidate hypotheses (none discriminated by evidence) include: a downstream phenolic metabolite rather than tyrosine itself; a human-specific critical developmental window; and ascertainment bias inflating the neurological association in a disorder historically found by investigating neurological symptoms.

Metabolomics / omics. The disease signature is a targeted metabolomic one (plasma amino acids: ↑tyrosine; urine organic acids: ↑4-hydroxyphenyl-lactate/-pyruvate/-acetate, absent succinylacetone). No transcriptomic, proteomic, single-cell, or functional-genomics screen data specific to HT III exist.

Suggested GO/CL/UBERON/CHEBI terms: GO:0003868, GO:0006572, GO:0006559 (L-phenylalanine catabolic process, adjacent); CHEBI:17895, CHEBI:15999, CHEBI:16169, CHEBI:18101; UBERON:0002107 (liver), UBERON:0002113 (kidney), UBERON:0000955 (brain, affected downstream); cell types not well-defined (hepatocyte CL:0000182; renal proximal tubule CL:1000838).

Sources: PMID:11073718, PMID:10942115, PMID:16602095, PMID:28649543; BRENDA EC 1.13.11.27; Wikipedia: 4-Hydroxyphenylpyruvate dioxygenase; P. fluorescens HPD crystal structure.

7. Anatomical Structures Affected

• Organ level (primary, metabolic): Liver (UBERON:0002107) and kidney (UBERON:0002113) — sites of HPD expression and of the metabolic block. Notably, these organs are biochemically affected but not structurally damaged.
• Organ level (clinically affected, downstream): Brain / central nervous system (UBERON:0000955; nervous system UBERON:0001016) — the site of the dominant clinical manifestations. Cranial imaging is usually normal; ventriculomegaly reported once (PMID:35707594).
• Body systems: Metabolic (amino-acid metabolism) primary; nervous system clinically dominant.
• Tissue/cell level: hepatocytes (CL:0000182) and renal proximal tubular epithelium (CL:1000838) carry the enzymatic defect; no specific neuronal population is implicated mechanistically.
• Subcellular level: HPD is cytosolic (GO:0005829 cytosol / GO:0005737 cytoplasm).
• Lateralization: Not applicable (systemic metabolic disease; neurological features bilateral/diffuse).

8. Temporal Development

• Onset: Biochemical abnormality is congenital (present from birth; detectable on newborn screening). Clinical/neurological onset is typically post-neonatal (infancy–childhood); pattern insidious to subacute (seizures can be acute).
• Progression: No defined staging. Course is variable — from stable/asymptomatic (screened, early-treated) to progressive neurodevelopmental impairment or acute seizure crises. It is a chronic, lifelong metabolic condition.

  "The majority of the nine previously reported patients have presented with neurological symptoms after the neonatal period, while others detected by neonatal screening have been asymptomatic." — PMID:11916315

• Patterns / critical periods: A putative early-infancy window where treatment may matter most is suspected but unproven:

  "It is not clear whether a strict low tyrosine diet alters the natural history of tyrosinaemia type III, although there remains a suspicion that treatment may be important, at least in infancy." — PMID:11916315

• Screened example of a benign early course: normal growth and psychomotor development at 30 months on mild protein restriction (PMID:23036342).
• Severe example: recurrent seizures at 4 months → status epilepticus at 6 months (PMID:29456978).

9. Inheritance and Population

Inheritance: Autosomal recessive (HP:0000007). Requires biallelic pathogenic HPD variants; heterozygous carriers are unaffected.

"Hereditary tyrosinemia type III (HT III) is an extremely rare form of tyrosinemia, characterized by autosomal recessive inheritance and biallelic mutations in the HPD gene." — PMID:37817461

• Penetrance: For the biochemical phenotype (hypertyrosinemia), effectively complete. For the neurological phenotype, incomplete and unpredictable (asymptomatic biallelic patients exist — PMID:28649543).
• Expressivity: Highly variable (mild ADHD/intellectual impairment → severe ID + status epilepticus), uncorrelated with genotype or tyrosine level (PMID:10942115).
• Genetic anticipation: Not applicable (not a repeat-expansion disorder).
• Founder effects / carrier frequency: No established founder allele; carrier frequency undetermined (too rare). Consanguinity contributes in reported families.

Epidemiology: - Prevalence/incidence: No robust population rate. Estimated incidence < 1 in 1,000,000; the rarest genetic tyrosinemia. ~19 patients reported worldwide as of 2022 (PMID:35707594); ~23 by 2025 counts. Curated prevalence class: BELOW_1_IN_1000000 (ultra-rare).

"Tyrosinemia type III is an extremely rare autosomal recessive disease, with only 19 patients yet reported." — PMID:35707594 - Geographic/ethnic distribution: No documented predisposition; cases reported across Europe, the Middle East, and East Asia. Ascertainment depends on whether a region's newborn-screening panel measures tyrosine. - Sex ratio: No established skew (cases in both sexes). - Age distribution: Neonatal (screened) or infancy–childhood (symptomatic).

Sources: PMID:35707594, PMID:32520295, PMID:11916315, PMID:37817461, PMID:23036342; Wadsworth NBS.

10. Diagnostics

Biochemical (first-line): - Plasma amino acids — elevated tyrosine (screening + monitoring analyte). LOINC candidates: Tyrosine [Moles/volume] in plasma. - Urine organic acids — elevated 4-hydroxyphenyl derivatives (4-OH-phenyllactate, -pyruvate, -acetate); succinylacetone ABSENT (excludes type I — the key discriminator).

"These disorders are diagnosed by observing elevated tyrosine by plasma amino acid chromatography and characteristic tyrosine metabolites by urine organic acid analysis." — PMID:16602095 "Urine organic acids show elevated p-hydroxy-phenyl organic acids in each type of tyrosinemia, and the pathognomic succinylacetone in tyrosinemia Type I." — PMID:16602095

Newborn screening: Detection of elevated tyrosine by tandem mass spectrometry (MS/MS) on dried blood spot. Note that MS/MS tyrosine is a poor primary marker for type I (succinylacetone is preferred there), but it does flag HT III/II and transient tyrosinemia. Confirmation requires repeat quantitation + urine organic acids + genetics (PMID:23036342).

Genetic testing: HPD single-gene / targeted NGS sequencing to identify biallelic pathogenic variants confirms diagnosis; HPD is offered on inborn-errors and tyrosinemia gene panels (also covers hawkinsinuria).

"A 3-year-old girl, identified through newborn screening, was diagnosed with HT III using targeted next-generation sequencing." — PMID:37817461

Enzyme assay: Direct hepatic HPD activity assay is possible but rarely needed given molecular testing.

Imaging / electrophysiology: Cranial MRI usually normal (ventriculomegaly reported once, PMID:35707594); EEG as indicated for seizures. Neither is diagnostic of HT III per se.

NCIT diagnostic terms: Laboratory Procedure (NCIT:C25294); Genetic Testing (NCIT:C15709).

Differential diagnosis: Transient tyrosinemia of the newborn (most common; resolves, non-genetic); tyrosinemia type I (FAH — succinylacetone+, liver/renal disease); tyrosinemia type II (TAT — oculocutaneous, no organic aciduria of this pattern); hawkinsinuria (HPD, dominant); liver disease causing secondary hypertyrosinemia; scurvy/ascorbate deficiency.

Sources: PMID:16602095, PMID:23036342, PMID:37817461; Oklahoma tyrosine screening fact sheet.

11. Outcome / Prognosis

• Survival/mortality: Not life-limiting through the metabolic lesion itself — no hepatic, renal, or oncologic risk (contrast type I). No disease-specific mortality data; life expectancy presumed normal.
• Morbidity/disability: Confined to the neurodevelopmental/behavioral domain. Long-term disability ranges from none (screened, treated) to significant intellectual disability with neurological abnormality (PMID:9343288).
• Complications: Seizures/status epilepticus (PMID:29456978); learning/behavioral difficulties.
• Recovery potential: Some patients report subjective gains after diet + falling tyrosine (PMID:35707594), but disease-modifying benefit is unproven.
• Prognostic factors: None validated. Age at dietary initiation is the leading candidate modifier (within-family sib comparison favored earlier treatment — PMID:32520295), but plasma tyrosine and genotype are not prognostic (PMID:10942115).

"All have had normal liver and renal function and none has skin or eye abnormalities." — PMID:11916315 (bounds the burden to the neurological domain)

12. Treatment

1. Dietary phenylalanine + tyrosine restriction (mainstay). Low-protein diet with a tyrosine-/phenylalanine-free amino-acid substitute ("anamix"-type formula). Reliably lowers plasma tyrosine; disease-modifying effect on neurology unresolved. - Modality: BEHAVIORAL/dietary. NCIT: Dietary Intervention (NCIT:C15447). - Target mechanism: reduces substrate delivery to the blocked step (INHIBITS "Hypertyrosinemia and phenolic metabolite accumulation").

"She was treated with a diet low in tyrosine and phenylalanine and anamix formula that leading to catch-up growth and improvement of her symptoms. Plasma tyrosine level dropped to normal values." — PMID:29456978 "Therapy consists of a diet low in phenylalanine and tyrosine for each of the tyrosinemias and 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) for tyrosinemia Type I." — PMID:16602095 "...a better neurological and behavioral evaluation in the patient who started treatment earlier." — PMID:32520295 (single sib pair; suggestive only)

2. Developmental/neurological supportive care. Antiseizure therapy, developmental/educational support, neurodevelopmental follow-up per phenotype. NCIT: Supportive Care (NCIT:C15747) (PMID:35707594).

Nitisinone (NTBC) — contraindicated in concept, not therapeutic here. Nitisinone is a pharmacological HPD inhibitor; it reproduces the HT III lesion rather than correcting it, and is confined to type I (and trialed in alkaptonuria). This is a key teaching point: the drug that treats type I would recreate the exact enzymatic block of type III.

Pharmacogenomics / advanced therapeutics / surgery / experimental trials: None applicable/reported. No gene, cell, RNA, or targeted therapy; no HT III–specific clinical trials (rarity).

Treatment outcomes: Biochemical response (falling tyrosine) is reliable; clinical/neurological response is variable and unproven as disease-modifying.

Sources: PMID:16602095, PMID:29456978, PMID:32520295, PMID:11916315, PMID:35707594, PMID:39290064 (NTBC-induced tyrosinemia toxicity in alkaptonuria).

13. Prevention

• Primary prevention: None (Mendelian). Genetic/reproductive counseling for at-risk families; carrier testing, prenatal diagnosis, and PGT-M are technically feasible where the familial variants are known. Consanguinity counseling relevant.
• Secondary prevention (early detection): Newborn screening for elevated tyrosine (MS/MS) enables presymptomatic diagnosis and early dietary intervention — the practical prevention lever, though its effect on neurological outcome is unproven.
• Tertiary prevention: Dietary control of tyrosine + neurodevelopmental monitoring to mitigate complications.
• Immunization / public-health / environmental interventions: Not applicable.

Sources: PMID:23036342; Wadsworth NBS.

14. Other Species / Natural Disease

• Taxonomy: Best-characterized non-human counterpart is mouse (Mus musculus, NCBITaxon:10090) — spontaneous "mouse strain III" with hereditary hypertyrosinemia.
• Ortholog: Mouse Hpd (NCBI Gene 15445); human HPD (NCBI Gene 3242). HPD is deeply conserved across mammals, plants, and bacteria (the enzyme is the target of HPPD-inhibitor herbicides).
• Natural disease / comparative biology: The mouse strain reproduces the human biochemical phenotype faithfully — absent hepatic HPD activity/protein, persistent hypertyrosinemia, urinary 4-hydroxyphenyl derivatives, no succinylacetone — while being "apparently healthy" (no overt neurological/hepatorenal disease). This species divergence (biochemical fidelity without the human neurodevelopmental phenotype) is itself informative for the neurotoxicity question. No prominent naturally occurring companion-animal/wildlife HT III is catalogued in OMIA.
• Transmission / zoonosis: Not applicable.

"These features are similar to type III tyrosinemia in humans." — PMID:2014797

15. Model Organisms

Mouse strain III (spontaneous Hpd-null mouse) — the principal and essentially only established model.

• Type: mammalian, spontaneous (pre-targeted-mutagenesis) inbred strain; autosomal recessive.
• Genotype/lesion: Hpd exon-7 nonsense substitution, homozygous, additionally causing skipping of the constitutive exon 7 in most transcripts → undetectable HPD subunit and virtually absent hepatic activity, with flanking enzymes (fumarylacetoacetase, both TAT isoforms) intact.

  "...4-hydroxyphenylpyruvic acid dioxygenase activity was virtually absent, while fumarylacetoacetase and tyrosine aminotransferases (cytosolic and mitochondrial forms) were normal..." — PMID:2014797 "We report a nucleotide substitution that generates a termination codon in exon 7 of the 4-hydroxyphenylpyruvic acid dioxygenase gene in III mice. This mutation is associated with partial exon skipping..." — PMID:7774914

• Phenotype recapitulation:
• HIGH fidelity for the enzyme block (RECAPITULATES): hepatic HPD activity and protein both null, pathway-specific.
• HIGH fidelity for the biochemical phenotype (RECAPITULATES): persistent hypertyrosinemia + ↑urinary 4-hydroxyphenylpyruvate derivatives + succinylacetone absent (the discriminating negative reproduced).
• FAILS TO RECAPITULATE the neurodevelopmental consequence: animals "apparently healthy," no hepatorenal dysfunction. Caveat: this is a negative on gross observation only — no standardized neurobehavioral/neurocognitive testing, neuropathology, or tyrosine-exposure calibration against the human range was performed. It therefore cannot be cited as evidence that hypertyrosinemia is neurologically harmless.

  "All the animals were apparently healthy, and there was no evidence of hepatorenal dysfunction." — PMID:2014797

• Model limitations: Murine allele (exon-7 nonsense/skipping), not a human patient allele — models complete LOF, not the hypomorphic missense genotypes common in patients; enzyme measured in liver only (renal HPD not assessed); metabolite panel qualitative, absolute tyrosine not human-calibrated.
• Applications: Studying the metabolic block and biochemistry of tyrosine catabolism; complements type I mouse models; available for (not-yet-done) neurobehavioral phenotyping to test the tyrosine-neurotoxicity hypothesis.
• Other systems: No non-animal experimental model (organoid/iPSC), no computational model, and no public omics dataset with a mechanism link specific to HT III were identified.

Sources: PMID:2014797, PMID:7774914.

Cross-cutting open questions (knowledge gaps)

1. Tyrosine neurotoxicity is unexplained. Neither HPD-lesion severity, residual enzyme activity, nor plasma tyrosine predicts the neurological phenotype, and biochemically affected patients with normal development exist. Candidate mediators (a downstream phenolic metabolite; a human-specific early developmental window; ascertainment bias) are undiscriminated. Proposed: prospective standardized neurocognitive follow-up of screened cohorts stratified by time-integrated tyrosine exposure (PMID:10942115, PMID:28649543).
2. Genetic vs pharmacological HPD block discrepancy. Nitisinone-induced (acquired) HPD blockade in type-I/alkaptonuria patients causes tyrosine corneal keratopathy and skin lesions; genetic HT III patients do not develop oculocutaneous disease. Possible explanations (higher absolute tyrosine under pharmacological block, residual activity in hypomorphs, tissue-distribution differences, older/longer-exposed nitisinone-treated adults) are unresolved and bear on whether HT III patients need ocular surveillance (PMID:11916315, PMID:39290064).
3. Mouse-model silence. The high-biochemical-fidelity Hpd-null mouse shows no overt neuro phenotype — but only gross observation was ever done; this is a HUMAN_MODEL_MISMATCH, not evidence of safety (PMID:2014797 vs PMID:35707594).

Consolidated Evidence Citations (PMIDs)

Web/database sources: OMIM #276710 · OMIM *609695 (HPD) · MedlinePlus: Tyrosinemia · Wikipedia: Tyrosinemia type III · StatPearls: Hypertyrosinemia · Wadsworth NBS: Tyrosinemia type III · ClinVar RCV000001640 · GTR: HPD gene 3242 · BRENDA EC 1.13.11.27 (human) · Wikipedia: 4-Hydroxyphenylpyruvate dioxygenase.

Note for KB curation: This report corresponds closely to the already-curated kb/disorders/Tyrosinemia_Type_III.yaml entry on this branch, which independently verifies each snippet against cached abstracts. The report adds contextualizing detail not carried in the YAML (gene locus 12q24.31 / 14 exons, UniProt P32754, EC/enzyme mechanism, ICD/OMIM-gene identifiers, transient-tyrosinemia differential, mouse Hpd Gene ID) that could enrich the entry; note that any such additions to the YAML would require their own verified PMID snippets (the enzyme-mechanism and locus facts above are sourced to BRENDA/OMIM/Wikipedia, not to the cached PMIDs, and should not be added as PMID-attributed evidence without fetching a citable primary source).

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.